Xinwei Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xinwei Jiang has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Yijie Lu
Department of Hepatobiliary Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Gusu School, Nanjing Medical University, Suzhou, 215000, China
4 shared publicationsZhiming Qiao
Department of Hepatobiliary Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Nanjing Medical University, Suzhou, People’s Republic of China
4 shared publicationsJianwu Wu
Department of Hepatobiliary Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Nanjing Medical University, Suzhou, People’s Republic of China
3 shared publications- Lining Huang
Department of Hepatobiliary Surgery, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
3 shared publications Song Li
Department of Hepatobiliary Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Gusu School, Nanjing Medical University, Suzhou, 215000, China
3 shared publicationsWeiqiao Niu
Department of Hepatobiliary Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Nanjing Medical University, Suzhou, People’s Republic of China
3 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-17
USP9X Promotes Hepatocellular Carcinoma Progression via Stabilization of HSP90AA1
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Ubiquitin-specific proteases (USPs) modulate tumor progression by regulating substrate protein stability. However, the mechanisms of most DUBs in HCC remain poorly understood. This study aimed to investigate the role of USP9X in promoting HCC cell proliferation, survival, migration, and invasion. Methods: Transcriptomic and clinical data of LIHC patients were obtained from TCGA to assess USP9X expression, prognosis, and pathway enrichment. USP9X expression in HCC and adjacent tissues was examined by immunohistochemistry and Western blotting. Functional assays (CCK-8, colony formation, wound-healing, Transwell) were performed following USP9X knockdown or overexpression in Lm3 and Huh7 cells. The USP9X–HSP90AA1 interaction was evaluated by Co-IP and mass spectrometry, and deubiquitination assays elucidated the mechanism. In vitro and in vivo experiments determined the effects of USP9X–HSP90AA1 signaling on HCC growth and metastasis. Results: Bioinformatic analyses revealed that USP9X expression was significantly elevated in LIHC tissues and correlated with poor prognosis. Immunohistochemistry and Western blotting confirmed higher USP9X protein levels in tumor tissues. Knockdown of USP9X inhibited proliferation and migration of Lm3 and Huh7 cells, whereas USP9X overexpression enhanced these phenotypes. Co-IP demonstrated a direct interaction between USP9X and HSP90AA1, and deubiquitination assays showed that USP9X decreased HSP90AA1 ubiquitination and increased its stability. Both in vitro and in vivo data indicated that USP9X promotes HCC progression through stabilization of HSP90AA1. Conclusion: USP9X is a tumor-promoting factor that accelerates HCC progression by stabilizing HSP90AA1, highlighting USP9X as a potential therapeutic target for HCC.
- 1 May 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-17
Open AccessUSP9X Promotes Hepatocellular Carcinoma Progression via Stabilization of HSP90AA1
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Ubiquitin-specific proteases (USPs) modulate tumor progression by regulating substrate protein stability. However, the mechanisms of most DUBs in HCC remain poorly understood. This study aimed to investigate the role of USP9X in promoting HCC cell proliferation, survival, migration, and invasion. Methods: Transcriptomic and clinical data of LIHC patients were obtained from TCGA to assess USP9X expression, prognosis, and pathway enrichment. USP9X expression in HCC and adjacent tissues was examined by immunohistochemistry and Western blotting. Functional assays (CCK-8, colony formation, wound-healing, Transwell) were performed following USP9X knockdown or overexpression in Lm3 and Huh7 cells. The USP9X–HSP90AA1 interaction was evaluated by Co-IP and mass spectrometry, and deubiquitination assays elucidated the mechanism. In vitro and in vivo experiments determined the effects of USP9X–HSP90AA1 signaling on HCC growth and metastasis. Results: Bioinformatic analyses revealed that USP9X expression was significantly elevated in LIHC tissues and correlated with poor prognosis. Immunohistochemistry and Western blotting confirmed higher USP9X protein levels in tumor tissues. Knockdown of USP9X inhibited proliferation and migration of Lm3 and Huh7 cells, whereas USP9X overexpression enhanced these phenotypes. Co-IP demonstrated a direct interaction between USP9X and HSP90AA1, and deubiquitination assays showed that USP9X decreased HSP90AA1 ubiquitination and increased its stability. Both in vitro and in vivo data indicated that USP9X promotes HCC progression through stabilization of HSP90AA1. Conclusion: USP9X is a tumor-promoting factor that accelerates HCC progression by stabilizing HSP90AA1, highlighting USP9X as a potential therapeutic target for HCC.
- 14 March 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 256, 116934
3D-guided planning enhances safety of laparoscopic resection for special liver segments: A propensity score-matched study
- 14 March 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 256, 116934
3D-guided planning enhances safety of laparoscopic resection for special liver segments: A propensity score-matched study
- Open Access
- 24 November 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (5) , 1873-1888
Prognostic and Immunological Significance of TIPARP in Pancreatic Cancer
Background Pancreatic ductal adenocarcinoma (PAAD) remains one of the most lethal malignancies, with a 5-year survival rate below 10%. TCDD-inducible poly (ADP-ribose) polymerase (TIPARP) is aberrantly expressed in various tumors, but its mechanistic role and clinical significance in pancreatic cancer remain unclear. Methods We analyzed TIPARP expression patterns and prognostic relevance by integrating data from the TCGA-PAAD (n = 178) and GTEx (n = 171) databases. Single-cell RNA sequencing, immune infiltration profiling, and Mendelian randomization analyses were conducted to assess cell-type specificity and causal relationships. The biological functions of TIPARP were validated through in vitro assays, and downstream mechanisms were explored via pathway enrichment analysis. Results TIPARP was significantly upregulated in pancreatic cancer tissues and correlated with worse overall survival (P = 5.9e − 3) and progression-free survival (P = 0.01), serving as an independent prognostic risk factor. A TIPARP-based nomogram exhibited strong predictive performance (C-index = 0.666; 5-year AUC = 0.885). Single-cell transcriptomics identified fibroblasts as the primary TIPARP-expressing cell type. Immune profiling revealed that high TIPARP expression was associated with altered immune cell infiltration and positively correlated with immune checkpoint molecules such as PD-L1 and TIM-3. Mendelian randomization confirmed a causal association between genetically predicted TIPARP expression and increased PAAD risk (OR = 1.511, P = 0.008). Functional assays showed that TIPARP promotes cell proliferation, migration, and invasion, while pathway analysis implicated the PI3K-Akt and ECM-receptor interaction signaling cascades. Conclusion TIPARP is a novel independent prognostic biomarker and potential therapeutic target in pancreatic cancer. It contributes to tumor progression by promoting an immunosuppressive microenvironment and activating pro-tumorigenic signaling. These findings highlight TIPARP as a promising candidate for precision medicine and combination immunotherapy in PAAD.
- 24 November 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (5) , 1873-1888
Open AccessPrognostic and Immunological Significance of TIPARP in Pancreatic Cancer
Background Pancreatic ductal adenocarcinoma (PAAD) remains one of the most lethal malignancies, with a 5-year survival rate below 10%. TCDD-inducible poly (ADP-ribose) polymerase (TIPARP) is aberrantly expressed in various tumors, but its mechanistic role and clinical significance in pancreatic cancer remain unclear. Methods We analyzed TIPARP expression patterns and prognostic relevance by integrating data from the TCGA-PAAD (n = 178) and GTEx (n = 171) databases. Single-cell RNA sequencing, immune infiltration profiling, and Mendelian randomization analyses were conducted to assess cell-type specificity and causal relationships. The biological functions of TIPARP were validated through in vitro assays, and downstream mechanisms were explored via pathway enrichment analysis. Results TIPARP was significantly upregulated in pancreatic cancer tissues and correlated with worse overall survival (P = 5.9e − 3) and progression-free survival (P = 0.01), serving as an independent prognostic risk factor. A TIPARP-based nomogram exhibited strong predictive performance (C-index = 0.666; 5-year AUC = 0.885). Single-cell transcriptomics identified fibroblasts as the primary TIPARP-expressing cell type. Immune profiling revealed that high TIPARP expression was associated with altered immune cell infiltration and positively correlated with immune checkpoint molecules such as PD-L1 and TIM-3. Mendelian randomization confirmed a causal association between genetically predicted TIPARP expression and increased PAAD risk (OR = 1.511, P = 0.008). Functional assays showed that TIPARP promotes cell proliferation, migration, and invasion, while pathway analysis implicated the PI3K-Akt and ECM-receptor interaction signaling cascades. Conclusion TIPARP is a novel independent prognostic biomarker and potential therapeutic target in pancreatic cancer. It contributes to tumor progression by promoting an immunosuppressive microenvironment and activating pro-tumorigenic signaling. These findings highlight TIPARP as a promising candidate for precision medicine and combination immunotherapy in PAAD.
- Open Access
- 4 October 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (40) , e39983
Case report and literature review: A young man with giant intra-abdominal Ewing sarcoma
Rationale: Extraosseous Ewing sarcoma (EES) is a rare manifestation within the Ewing sarcoma tumor family (ESFT). Its clinical manifestations lack specificity, intestinal obstruction is the main symptom but can also present with abdominal pain, gastrointestinal bleeding, and other discomforts, making it prone to misdiagnosis as intestinal mesenchymal tumor. Patient concerns: A 29-year-old male was admitted to the hospital with intestinal obstruction symptoms and abdominal CT suggesting “left abdominal occupation.” Diagnosis: The patient was initially misdiagnosed as intestinal mesenchymal tumor, and was later definitively diagnosed as abdominal Ewing sarcoma by postoperative pathology and genetic testing. Interventions: Due to the patient’s surgical indication, surgical resection with exploratory laparotomy was performed and then the patient underwent systemic chemotherapy. Outcomes: Intraoperatively, we found a 15-cm tumor originating from the proximal jejunum, with invasion into the peritoneum, duodenum, jejunum, and colon. Finally, the pathological report revealed Ewing sarcoma. Lessons: Giant abdominal Ewing sarcoma with a diameter of 15 cm is rare. Considering postoperative pathology and genetic testing, abdominal Ewing sarcoma was suspected. The patient was successfully treated using surgery.
- 4 October 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (40) , e39983
Open AccessCase report and literature review: A young man with giant intra-abdominal Ewing sarcoma
Rationale: Extraosseous Ewing sarcoma (EES) is a rare manifestation within the Ewing sarcoma tumor family (ESFT). Its clinical manifestations lack specificity, intestinal obstruction is the main symptom but can also present with abdominal pain, gastrointestinal bleeding, and other discomforts, making it prone to misdiagnosis as intestinal mesenchymal tumor. Patient concerns: A 29-year-old male was admitted to the hospital with intestinal obstruction symptoms and abdominal CT suggesting “left abdominal occupation.” Diagnosis: The patient was initially misdiagnosed as intestinal mesenchymal tumor, and was later definitively diagnosed as abdominal Ewing sarcoma by postoperative pathology and genetic testing. Interventions: Due to the patient’s surgical indication, surgical resection with exploratory laparotomy was performed and then the patient underwent systemic chemotherapy. Outcomes: Intraoperatively, we found a 15-cm tumor originating from the proximal jejunum, with invasion into the peritoneum, duodenum, jejunum, and colon. Finally, the pathological report revealed Ewing sarcoma. Lessons: Giant abdominal Ewing sarcoma with a diameter of 15 cm is rare. Considering postoperative pathology and genetic testing, abdominal Ewing sarcoma was suspected. The patient was successfully treated using surgery.
- Open Access
- 26 September 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1236685
Multivisceral resection of nonfunctional pancreatic neuroendocrine neoplasm with nearby organ invasion: a case report
Pancreatic neuroendocrine neoplasms (pNENs) are relatively rare epithelial malignancies originating from pancreatic neuroendocrine cells, pathologically classified into well-differentiated pancreatic neuroendocrine tumors (pNETs) and poorly-differentiated pancreatic neuroendocrine carcinoma (pNECs). Although they also fall under the category of pNENs, the almost entirely distinct biological characteristics and survival prognosis have caused debate among surgeons when it comes to the development of surgical intervention options, particularly for locally advanced G3 pNETs and pNECs. We present a case of 66-year-old male with nonfunctional G3 pNET, invasion of five nearby pancreatic organs and type II liver metastases. The patient achieved good outcomes after undergoing multivisceral resection and postoperative adjuvant chemotherapy. This finding helps surgeons better understand locally advanced pNENs, formulate treatment decisions systematically and confidently, and balance patient benefits and risks of surgery.
- 26 September 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1236685
Open AccessMultivisceral resection of nonfunctional pancreatic neuroendocrine neoplasm with nearby organ invasion: a case report
Pancreatic neuroendocrine neoplasms (pNENs) are relatively rare epithelial malignancies originating from pancreatic neuroendocrine cells, pathologically classified into well-differentiated pancreatic neuroendocrine tumors (pNETs) and poorly-differentiated pancreatic neuroendocrine carcinoma (pNECs). Although they also fall under the category of pNENs, the almost entirely distinct biological characteristics and survival prognosis have caused debate among surgeons when it comes to the development of surgical intervention options, particularly for locally advanced G3 pNETs and pNECs. We present a case of 66-year-old male with nonfunctional G3 pNET, invasion of five nearby pancreatic organs and type II liver metastases. The patient achieved good outcomes after undergoing multivisceral resection and postoperative adjuvant chemotherapy. This finding helps surgeons better understand locally advanced pNENs, formulate treatment decisions systematically and confidently, and balance patient benefits and risks of surgery.
- 15 August 2022
- Vol. 12 (8) , 3625-+
Brachyury promotes proliferation and migration of hepatocellular carcinoma via facilitating the transcription of NCAPG2
Hepatocellular carcinoma (HCC) has a poor prognosis because of its limited drug responses in clinical trials. Therefore, it is crucial to clarify the molecular mechanisms of HCC progression to identify new diagnostic markers and therapeutic targets. Here, we report that brachyury, which regulates the gene encoding the non-SMC condensin II complex subunit G2 (NCAPG2), promotes tumorigenesis in HCC. Knockdown of brachyury led to inhibition of cancer progression in vitro and in vivo. Chromatin immunoprecipitation-sequencing data indicated that the oncogene NCAPG2 is a direct target of brachyury. Furthermore, NCAPG2 knockdown inhibited the proliferation and migration of HCC cells and attenuated brachyury-induced tumorigenesis. Overexpression and decreased DNA methylation of NCAPG2 were associated with a poor prognosis, and NCAPG2 was positively correlated with various immune cell infiltrates, cancer-associated fibroblasts, and immune checkpoint molecule expression levels in the tumor microenvironment. Moreover, the effectiveness of immune checkpoint blockade was decreased in the high NCAPG2 expression group. Together, these findings demonstrated a coregulatory effect of the brachyury/NCAPG2 axis during HCC progression.
- 15 August 2022
- Vol. 12 (8) , 3625-+
Brachyury promotes proliferation and migration of hepatocellular carcinoma via facilitating the transcription of NCAPG2
Hepatocellular carcinoma (HCC) has a poor prognosis because of its limited drug responses in clinical trials. Therefore, it is crucial to clarify the molecular mechanisms of HCC progression to identify new diagnostic markers and therapeutic targets. Here, we report that brachyury, which regulates the gene encoding the non-SMC condensin II complex subunit G2 (NCAPG2), promotes tumorigenesis in HCC. Knockdown of brachyury led to inhibition of cancer progression in vitro and in vivo. Chromatin immunoprecipitation-sequencing data indicated that the oncogene NCAPG2 is a direct target of brachyury. Furthermore, NCAPG2 knockdown inhibited the proliferation and migration of HCC cells and attenuated brachyury-induced tumorigenesis. Overexpression and decreased DNA methylation of NCAPG2 were associated with a poor prognosis, and NCAPG2 was positively correlated with various immune cell infiltrates, cancer-associated fibroblasts, and immune checkpoint molecule expression levels in the tumor microenvironment. Moreover, the effectiveness of immune checkpoint blockade was decreased in the high NCAPG2 expression group. Together, these findings demonstrated a coregulatory effect of the brachyury/NCAPG2 axis during HCC progression.
- 1 February 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 522 (3) , 716-723
miR-1470 regulates cell proliferation and apoptosis by targeting ALX4 in hepatocellular carcinoma
- 1 February 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 522 (3) , 716-723
miR-1470 regulates cell proliferation and apoptosis by targeting ALX4 in hepatocellular carcinoma